Life Sciences: Biotech
Vaccine for cancer finds a patron
$50m pledge will help Therion develop drug
In an unusual effort by a single wealthy investor to keep a medical idea alive, a German billionaire is promising $50 million to Therion Biologics Corp., a small Cambridge company trying to develop the first-ever therapeutic vaccine for cancer. (Full article: 1076 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
